{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:29:02Z","timestamp":1785443342597,"version":"3.56.0"},"reference-count":49,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Belantamab mafodotin (belamaf) has shown promising antimyeloma activity in relapsed or refractory multiple myeloma (RRMM) as a single agent. It was hypothesized that its multimodal activity may be enhanced by programmed cell death protein 1 pathway inhibition and activation of T cell\u2013mediated antitumor responses. This study investigated the efficacy and safety of belamaf with pembrolizumab in patients with RRMM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>DREAMM\u20104 (NCT03848845) was an open\u2010label, single\u2010arm, phase 1\/2 study divided into dose\u2010escalation (part 1) and dose\u2010expansion (part 2) phases. Patients were \u226518 years old with \u22653 prior lines of therapy including a proteasome inhibitor, an immunomodulatory drug, and an anti\u2010CD38 agent. Patients received belamaf (2.5 or 3.4 mg\/kg, part 1; 2.5 mg\/kg, part 2) and 200 mg pembrolizumab for \u226435 cycles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 41 enrolled patients, 34 (<jats:italic>n<\/jats:italic>\u00a0=\u00a06 part 1, <jats:italic>n<\/jats:italic>\u00a0=\u00a028 part 2) who received 2.5 mg\/kg belamaf plus pembrolizumab were included in this final analysis. Sixteen patients (47%) achieved an overall response. Minimal residual disease negativity was achieved in three of 10 patients who had very good partial response or better. Five of eight patients who had prior anti\u2013B\u2010cell maturation antigen therapy achieved partial response or better, including two who had B\u2010cell maturation antigen\u2013refractory disease. Common grade \u22653 adverse events were keratopathy (38%) and thrombocytopenia (29%). Despite belamaf\u2010related ocular events, quality\u2010of\u2010life measures remained stable over time. No new safety signals were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results of DREAMM\u20104 demonstrated clinical activity and a favorable safety profile of belamaf plus pembrolizumab in patients with RRMM. This trial is registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\/\">www.ClinicalTrials.gov<\/jats:ext-link> as <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\/show\/NCT02420912\">NCT03848845<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.35319","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T14:24:25Z","timestamp":1713363865000},"page":"2629-2641","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma"],"prefix":"10.1002","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9445-8781","authenticated-orcid":false,"given":"Attaya","family":"Suvannasankha","sequence":"first","affiliation":[{"name":"Indiana University Simon Cancer Center and Roudebush VAMC  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[{"name":"Arnie Charbonneau Cancer Research Institute University of Calgary  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Koenecke","sequence":"additional","affiliation":[{"name":"Hannover Medical School Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation  Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras Hospital Germans Trias i Pujol  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute Atrium Health\/Wake Forest University School of Medicine  Charlotte North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aranzazu A.","family":"Alonso","sequence":"additional","affiliation":[{"name":"Hospital Universitario Quir\u00f3nsalud Madrid  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[{"name":"Carbone Cancer Center University of Wisconsin  Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda\u2010Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca and Centro de Investigaci\u00f3n del C\u00e1ncer Hospital Universitario de Salamanca  Salamanca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishitha","family":"Reddy","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Hakim","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"LaMacchia","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline  Waltham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashita","family":"Patel","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline  Stevenage UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana\u00e9","family":"Williams","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne C.","family":"Jewell","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Zhou","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Gupta","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Opalinska","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-6869","authenticated-orcid":false,"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute Emory University Hospital  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(21)00135\u20105"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.09.001"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21771"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010022\u201005058\u20105"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/20499361211036773"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(19)30788\u20100"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(18)30576\u2010x"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12660"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.mct\u201021\u20100035"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33809"},{"key":"e_1_2_11_12_1","volume-title":"Prescribing information","author":"Keytruda (pembrolizumab)","year":"2022"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/coc.0000000000000239"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v124.21.291.291"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.104"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15888"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201003\u2010775122"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15946"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(19)30110\u20103"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(19)30109\u20107"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/antib8020034"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1254856"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1729022"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.11.024"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010019\u20100432\u20104"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549\u2010021\u201006423\u20100"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943\u2010019\u20100974\u20106"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02431"},{"key":"e_1_2_11_29_1","unstructured":"Study evaluating safety tolerability and clinical activity of GSK2857916 in combination with pembrolizumab in subjects with relapsed\/refractory multiple myeloma (RRMM) (DREAMM 4). ClinicalTrials.gov identifier: NCT03848845. Accessed November 3 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03848845"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(16)30206\u20106"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774510382799"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.8018"},{"key":"e_1_2_11_33_1","volume-title":"Onco\u2010Nephrology Curriculum","author":"Leung NR","year":"2016"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774508089279"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.446"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102020\u2010140013"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201008\u2010731885"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010164877"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(23)00243\u20100"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000970760.35249.ae"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720979813"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143507"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201015\u20102224"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010020\u201000369\u20100"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061819"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01771"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010018\u20100589\u20101"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd\u201020\u20101661"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.36_suppl.439572"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002703\u2010y"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.35319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:08:49Z","timestamp":1760263729000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.35319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":49,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/cncr.35319"],"URL":"https:\/\/doi.org\/10.1002\/cncr.35319","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,17]]},"assertion":[{"value":"2023-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}